Poland – Programming services of application software – Zaprojektowanie, wykonanie, wdrożenie oraz świadczenie asysty technicznej i konserwacji aplikacji SOZP 2.0 służącej do obsługi zamówień publicznych w Gminie Miejskiej Kraków oraz udzielenie licencji.

Poland – Media storage and reader devices – Dostawa, instalacja, konfiguracja i wdrożenie 2 szt. macierzy wraz z oprogramowaniem na potrzeby rozbudowy ośrodków przetwarzania danych MRPiPS

Poland – Software package and information systems – Dostawa oprogramowania do budowy chmury prywatnej - postępowanie w celu zawarcia umowy ramowej

Poland – Technical computer support services – Asysta techniczna i wsparcie serwisowe systemu RayStation

Poland – Systems support services – Odnowienie licencji i wsparcia dla elementów infrastruktury krytycznej.

Poland – Software package and information systems – dostawa i wdrożenie systemu oprogramowania szpitalnego HIS w ramach realizacji zadania „Poprawa poziomu dojrzałości cyfrowej w Powiatowym Centrum Medycznym Spółka z o.o. w Braniewie poprzez rozbudowę infrastruktury IT” w ramach Priorytetu 01 Gospodarka Działania 01.07 E-zdrowie, z Programu Regionalnego – Fundusze Europejskie dla Warmii i Mazur 2021-2027 – współfinansowanego ze środków Europejskie

Poland – Systems and technical consultancy services – Pełnienie funkcji Inżyniera Kontraktu w ramach projektu „ROZBUDOWA SYSTEMU RIS NA ODRZAŃSKIEJ DRODZE WODNEJ”

The opportunity for the Federal Aviation Administration (FAA) Center of Excellence for Alternative Jet Fuel and Environment (AJFE) was awarded in 2013 to the ASCENT cooperative aviation research organization. ASCENT is a coalition of 16 leading US research universities committed to improving the understanding of aviation noise and emissions and the modeling of aviation systems. ASCENT is co-led by Washington State University and the Massachusetts Institute of Technology (https://ascent.aero/). Any new grant opportunities under AJFE are open and available only to the university members of ASCENT.”

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…